Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
HIV/AIDS
•
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Infectious Disease
•
Immunosuppression
What is your approach for managing DMARDs in patients with rheumatoid arthritis and newly diagnosed HIV?
Related Questions
How do you approach restarting cDMARDS/bDMARDS in a patient with active RA after incidence of disseminated CNS VZV infection while on tofacitinib?
Is it ever safe to use a biologic DMARD in a patient with RA who is on suppressive antibiotics due to a history of septic prosthetic arthritis?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
How often do you see bony erosions in patients with Lyme arthritis?
How would you approach a patient with seronegative RA and ILD?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
